

1 **¹⁸F-NaF Uptake on Vascular PET Imaging in Symptomatic versus Asymptomatic**
2 **Atherosclerotic Disease: a Meta-Analysis**

3 Bhakta S¹, Chowdhury MM², Tarkin JM³, Rudd JHF³, Warburton EA¹, Evans NR¹

4

5 ¹Department of Clinical Neurosciences, University of Cambridge, Cambridge. CB2 0QQ

6 ²Department of Vascular Surgery, University of Cambridge, Cambridge. CB2 0QQ

7 ³Division of Cardiovascular Medicine, University of Cambridge, Cambridge. CB2 0QQ

8

9 Corresponding author:

10 Nicholas Evans

11 R3 Clinical Neurosciences

12 Addenbrooke's Hospital

13 Cambridge

14 CB2 0QQ

15

16 Email: ne214@cam.ac.uk

17 Twitter: [@nr_evans](https://twitter.com/nr_evans)

18

19 Word count: 6634

20

21 **Abstract**

22

23 **Introduction**

24

25 ¹⁸F-sodium fluoride (NaF) positron-emission tomography (PET) is increasingly being used to
26 measure microcalcification in atherosclerotic disease *in vivo*. Correlations have been drawn
27 between sodium fluoride uptake and the presence of high-risk plaque features, as well as its
28 association with clinical atherosclerotic sequelae. The aim of this review was to perform a
29 meta-analysis of NaF uptake on PET imaging and its relation to symptomatic and
30 asymptomatic disease.

31

32 **Methods**

33

34 A systematic review was performed according to PRISMA guidelines, via searching the
35 MEDLINE database up to August 2023. The search strategy included the terms “NaF”, “PET”
36 and “plaque”, and all studies were included where there was data listed regarding the
37 degree of microcalcification, as measured by ¹⁸F-NaF uptake in symptomatic and
38 asymptomatic atherosclerotic plaques. Analysis involved calculating standardized mean
39 differences between uptake values and comparison using a random-effects model.

40

41 **Results**

42

43 A total of 15 articles, involving 423 participants, were included in the meta-analysis.
44 Comparing ¹⁸F-NaF uptake in symptomatic vs asymptomatic atherosclerotic plaques, a
45 standardized mean difference of 0.42 (95% CI 0.29-0.56; $p < 0.001$, $I^2 = 54.1\%$) was noted for
46 those studies comparing symptomatic and asymptomatic plaques in the same participant,
47 with no significant change in effect based on arterial territory studied ($Q_M = 5.02$, $p = 0.08$).
48 In those studies where data was included from participants with and without symptomatic
49 disease, the standardized mean difference between symptomatic and asymptomatic
50 plaques was 0.44 (95% CI 0.03-0.85, $p = 0.037$, $I^2 = 40.4\%$). All studies including asymptomatic
51 participants were investigating carotid disease.

52

53 Conclusions

54

55 PET imaging using ^{18}F -NaF can detect differences in microcalcification between symptomatic
56 and asymptomatic atherosclerotic plaques within and between individuals, and is a marker
57 of symptomatic disease. The standardization of ^{18}F -NaF PET imaging protocols, and its future
58 use as a risk stratification tool or outcome measure, requires further study.

59

60 **Non-standard Abbreviations and Acronyms**

61

62 MDS – most diseased segment

63 NaF – sodium fluoride

64 ROI – region of interest

65 SUV – standardized uptake value

66 TBR – tissue-to-background ratio

67 TBRmax – maximum tissue-to-background ratio from the region of interest

68 Introduction

69

70 Atherosclerosis is a systemic chronic arterial disease¹, involving the accumulation of lipids
71 and inflammatory cells² to form foci of disease, termed ‘plaques’, at the vessel wall. It is the
72 cause of over one third of all deaths³, through resulting diseases such as myocardial
73 infarction, ischemic stroke, and critical limb threatening ischemia. In some patients, minor
74 or less severe clinical symptoms may be a marker of higher risk for progressing to more
75 severe clinical disease, such as stable angina preceding myocardial infarction^{4,5}, or transient
76 ischemic attack, conferring a higher risk of ischemic stroke in the short term^{6,7}.

77

78 Plaques may have heterogenous appearances⁸, with certain plaque features indicating a
79 higher risk of rupture and subsequent clinical sequelae^{8,9}. These high-risk features include
80 the presence of a lipid-rich necrotic core¹⁰, intraplaque hemorrhage¹¹, a thin or ruptured
81 fibrous cap¹², and the presence of microcalcification¹³. The mechanisms determining the
82 transition from a low-risk (“stable”) to a high-risk (“unstable”) plaque and vice versa are
83 incompletely understood^{14,15}, but microcalcification has been recognized as a potential
84 cause for acute plaque rupture, through mechanical destabilization of the fibrous cap of the
85 plaque¹⁶, as well as causing an increased inflammatory response within the plaque¹⁷, leading
86 to enzymatic destabilization of the plaque¹⁸. Microcalcifications are calcium deposits of
87 <50µm in diameter, which is below the spatial resolution of commonly-used clinical vascular
88 imaging techniques¹⁹, such as computed tomography (CT) or magnetic resonance imaging
89 (MRI).

90

91 Positron emission tomography (PET) is a nuclear imaging technique used in vascular imaging
92 due to its high sensitivity to detect low concentrations of radiolabeled ligands (termed
93 “tracers”), which can be directed to detect the presence of a specific target or process²⁰.
94 Sodium fluoride (NaF), labelled with fluorine-18, has been validated as a tracer for the
95 identification of microcalcification in vascular imaging²¹.

96

97 NaF adsorbs to the surface of hydroxyapatite within the body²², with hydroxyapatite being
98 the most common calcium-containing crystal structure in atherosclerotic plaques *in vivo*^{23,24}.
99 Fluorine exchanges with hydroxyl groups on the surface of these crystals, while there is

100 substantially less tracer uptake deeper within the crystal structure of the molecule²².
101 Calcium deposits with an increased surface area therefore have increased fluoride ion
102 uptake over the uptake durations used in clinical PET scanning^{22,25}. Using NaF, this process
103 of hydroxyl-ion substitution can be used to detect microcalcifications via PET imaging. Due
104 to their high surface area to volume ratio, microcalcifications will demonstrate higher
105 uptake on PET compared to areas with no microcalcification, or those with larger deposits of
106 calcium (“macrocalcification”)²⁶⁻²⁸. NaF-PET can be preferred for vascular imaging compared
107 to other PET imaging techniques for visualizing high-risk plaques due to issues, such as ‘spill-
108 over artefact’ when using fluorodeoxyglucose (FDG)-PET in cardiac imaging.

109

110 There is an increasing body of literature demonstrating the use of NaF-PET for vascular
111 imaging in atherosclerosis²⁹, and specifically, in symptomatic disease. This meta-analysis
112 focuses on the role of NaF-PET imaging to differentiate between symptomatic versus
113 asymptomatic atherosclerotic disease.

114

115 **Methods**

116

117 **Protocol, Search Strategy and Selection Criteria**

118

119 Details for the protocol were registered on PROSPERO³⁰. The selection process and
120 reporting items were based on the preferred reporting items for systematic reviews and
121 meta-analysis (PRISMA) flow diagram and checklist³¹. The primary outcome was to
122 determine differences in NaF tracer uptake between symptomatic and asymptomatic
123 atherosclerotic plaques. A search strategy was formulated using Embase and Medline All via
124 Ovid (**Figure 1**). Additionally, a manual search was performed to identify relevant records
125 through reference searches. Duplicate records were removed, and the retrieved records
126 were checked for inclusion and exclusion criteria.

127

128 Studies were eligible for inclusion if they investigated the association between NaF uptake
129 and symptomatic and asymptomatic atherosclerotic plaques, where symptomatic plaques
130 were those that were associated with a recent clinical vascular event, including, but not
131 limited to, stroke or myocardial infarction, while asymptomatic plaques were those not

132 associated with a recent clinical vascular event. Studies were excluded if animal data was
133 used, non-atherosclerotic disease was investigated, or if the study did not provide details
134 regarding the type or location of symptomatic disease.

135

136 Data Selection, Extraction and Quality Assessment

137

138 Data were extracted by one study investigator (S. B.) and checked by another researcher (N.
139 R. E.), from the included records, using a standardized electronic data collection form.
140 Discrepancies were resolved by re-extraction or by third-party adjudication (E. A. W.) as
141 required. Retrieved characteristics from the studies included, but was not limited to, the
142 number of subjects, patient population, targeted vascular territory, dose of NaF injected,
143 uptake time, imaging protocols, primary endpoint measures for PET/CT and main findings,
144 which were tabulated as per published guidance³². The ROBINS-E tool³³ was used to assess
145 the quality of the studies included in this review (**Supplementary Figure 1**).

146

147 Statistical Analysis

148

149 The mean and associated standard deviation (SD), or the median and the associated
150 interquartile range (IQR) of the measurement of NaF signal were extracted from the
151 included studies. Extracted median and IQR data was converted into mean and SD data in
152 order to calculate a unified outcome³⁴. In studies where multiple measures of NaF signal
153 were listed, the value corresponding to the TBR related to the maximum SUV value (TBR_{max})
154 was taken. The absolute difference between the populations when NaF signal is measured
155 using SUV versus TBR is minor, given the low blood pool activity of NaF following an
156 appropriate uptake time¹⁹.

157

158 Studies were classified by their included participants – those with only symptomatic
159 participants, or those also including an asymptomatic control population. The effect
160 estimates from each study were pooled using the inverse-variance weighted method, and
161 random effects models were used for meta-analysis. I^2 statistics were calculated to
162 determine the variability in effect estimate due to between-study heterogeneity. Meta-
163 analyses were performed where there were two or more studies using the same type of

164 included population. Standardized mean differences were calculated due to the variability in
165 reporting outcomes used in the included studies.

166

167 Funnel plots (**Figures 2 and 3**) were used to visually assess the symmetry of the studies
168 about the mean effect size, to identify any publication bias. Two-tailed tests were used, and
169 a *p*-value of 0.05 was taken as the limit of statistical significance. Statistical analyses were
170 performed using the *metafor*³⁵ and *metamedian*³⁶ packages, using R Statistical Software
171 (v4.3.1, R Core Team 2023).

172

173 Subgroup analysis was performed between the different arterial territories assessed in the
174 included studies to generate standardized mean difference measurements for symptomatic
175 atherosclerotic plaques compared with asymptomatic plaques, and to determine any
176 statistical differences in NaF uptake between different arterial territories.

177

178 **Results**

179

180 **Included Studies**

181

182 A total of 966 titles were initially identified from the search (**Figure 4**)³⁷. Manual de-
183 duplication of results was performed, and the remaining 733 records underwent manual
184 screening of the titles and abstracts³⁸. Of those, 636 were excluded as not meeting the
185 inclusion criteria. 97 articles were therefore sought for retrieval. Five articles were not
186 available for analysis and 92 articles were therefore assessed for eligibility through full-text
187 review. Of these, 77 were excluded, 53 due to not reporting outcomes related to
188 symptomatic atherosclerotic disease, 15 due to no documented comparison between
189 symptomatic and asymptomatic disease, eight due to discussion of imaging protocols and
190 quality assessment and one due to reporting outcome measures insufficient for meta-
191 analysis. The remaining 15 articles were included in the meta-analysis, and form the study
192 population analyzed. A summary of study details is shown in **Tables 1 and 2**, dichotomized
193 based on the comparator of symptomatic disease used in each study.

194

195 Comparative intra-individual ¹⁸F-NaF tracer uptake between symptomatic and
196 asymptomatic atherosclerotic disease

197

198 Ten studies, including 352 participants, reported data in participants comparing NaF uptake
199 in the symptomatic atherosclerotic plaque compared to asymptomatic plaques within the
200 same participant's vascular territory being observed, including data for 317 symptomatic,
201 and 336 asymptomatic plaques (**Table 1**).

202

203 Pooled comparisons of these studies demonstrated a significantly higher uptake in
204 symptomatic lesions compared to asymptomatic plaques (standardized mean difference
205 0.42, 95% CI 0.29-0.56, $p < 0.001$, **Figure 5**). Subgroup analysis to compare results from
206 different arterial territories showed no significant difference in this relationship based on
207 the site of the symptomatic plaque ($Q_M = 5.02$, $p = 0.08$). Significant heterogeneity was
208 noted between the studies ($Q = 19.89$, $I^2 = 54.1\%$, $p = 0.019$).

209

210 Comparative NaF tracer uptake in symptomatic and asymptomatic atherosclerotic plaques
211 where a healthy control population was included

212

213 Five studies, including 71 participants, reported data in participants comparing NaF uptake
214 in the symptomatic atherosclerotic plaque compared to asymptomatic plaques, pooling data
215 from asymptomatic disease within the same symptomatic individual and plaques from
216 asymptomatic healthy controls, including data for 47 symptomatic, and 63 asymptomatic
217 plaques (**Table 2**).

218

219 Analysis of the pooled data from these studies demonstrated a significantly higher NaF
220 uptake in symptomatic atherosclerotic lesions compared to asymptomatic lesions, present
221 in the same individuals, or in healthy controls (standardized mean difference 0.44, 95% CI
222 0.03-0.85, $p = 0.037$, **Figure 6**). All studies analyzed assessed atherosclerotic disease within
223 the carotid arteries, and subgroup analysis for differences between different arterial
224 territories was therefore not conducted. There was no significant heterogeneity between
225 studies included in this analysis ($Q = 6.37$, $I^2 = 40.4\%$, $p = 0.17$).

226

227 **Discussion**

228

229 These results demonstrate the utility of NaF-PET, combined with CT or MRI, to differentiate
230 between symptomatic and asymptomatic atherosclerotic disease in a number of different
231 vascular territories. Studies have also demonstrated a correlation between NaF uptake and
232 high-risk morphological features on MRI, such as the presence of a lipid-rich necrotic core,
233 or intraplaque haemorrhage³⁹. In addition, there is emerging evidence of a prognostic link
234 between NaF signal on PET and the risk of recurrent disease⁴⁰, where coronary NaF imaging
235 had the ability to predict myocardial infarction and cardiovascular death.

236

237 As noted in **Tables 1 and 2**, there are a range of different doses of NaF used, along with a
238 non-standardized uptake time, blood pool measurement for TBR calculations, and outcome
239 measurement. Irkle et al²⁵ demonstrated an optimum uptake time of around 60 minutes,
240 based on *in vitro* and *in vivo* data. However, NaF-PET lacks a consensus on best practice, in
241 contrast to vascular FDG-PET imaging, following the 2005 position paper from the European
242 Association of Nuclear Medicine⁴¹. Having a standardized methodology for performing and
243 analyzing vascular NaF imaging would allow increased comparability and reproducibility
244 between studies.

245

246 There was also significant heterogeneity in the included studies between the time of
247 symptom onset and imaging being performed. There is little data concerning the temporal
248 changes in microcalcification and NaF uptake following an acute atherosclerotic event, and
249 further information on the optimum time period for imaging microcalcification in relation to
250 symptomatic disease could further standardize imaging protocols and improve robustness
251 of outcomes measured using NaF-PET as a surrogate marker.

252

253 In atherosclerosis, PET has been demonstrated to have a high sensitivity for the target
254 pathophysiology and can be combined with other imaging modalities to provide additional
255 utility, such as in combination with CT and CT angiography to assess for stenotic disease⁴²
256 and calcium scores in the coronary vasculature⁴³, or with MRI, to identify high risk
257 appearances as discussed above⁴⁴. In vascular imaging, NaF may be superior to FDG as it
258 may have a superior ability to discriminate between symptomatic and asymptomatic disease

259 in high-risk individuals⁴⁵. In addition, NaF does not require fasting prior to the uptake
260 period, and can be used with a shorter uptake time compared to FDG-PET^{25,41}. NaF is also
261 less susceptible to spill-over artefact, such as from the myocardium, which can limit FDG-
262 based PET imaging of the arteries⁴⁵. However, the cost, radiation exposure and uptake and
263 scanning time mean the role of PET imaging in routine clinical assessment of atherosclerotic
264 disease is currently limited.

265

266 Microcalcification is known to confer an increased risk of plaque rupture through
267 enzymatic¹⁸ and mechanical¹⁷ destabilization of the plaque surface. Therefore, targeting this
268 process may reduce the risk of early recurrence following symptomatic atherosclerotic
269 disease. NaF-PET can be utilized to assess responses to clinical interventions, given its
270 accuracy and sensitivity in determining differences in the presence of microcalcification *in*
271 *vivo*⁴⁶. Additionally, the process by which microcalcification evolves into macrocalcification,
272 which is thought to be protective for the atherosclerotic plaque, is poorly defined and
273 understood⁴⁷. Temporal evaluation of the microcalcification-macrocalcification process
274 through NaF-PET/CT could shed more light on the factors which confer a greater or lesser
275 degree of risk with calcification in atherosclerosis. In addition, NaF imaging could potentially
276 have a role in risk stratification in patients where there is uncertainty about the risk of
277 recurrent stroke or the need for surgical intervention, which is particularly relevant for
278 those with moderate 50-69% stenoses.

279

280 **Conclusion**

281

282 Our findings support vascular NaF-PET imaging as a reliable method for assessment of
283 atherosclerotic disease that is able to help differentiate between symptomatic/vulnerable
284 plaques and asymptomatic/stable plaques. The majority of data involves analysis of the
285 carotid or coronary circulation, but NaF-PET imaging is also a viable imaging technique in
286 other arterial territories. There is a potential future role of NaF-PET in clinical
287 atherosclerosis imaging and providing surrogate markers of impact in interventional trials,
288 but harmonization of imaging protocols including outcome measures, injected doses and
289 uptake times is required to ensure comparability between studies.

290

291 **Funding**

292

293 SB is supported by a Research Training Fellowship from The Dunhill Medical Trust
294 [JBGS22\20]. The ICARUSS study was supported as part of a Research Training Fellowship
295 awarded to NRE by The Dunhill Medical Trust [RTF44/0114], and by the NIHR Cambridge
296 Biomedical Research Centre (NIHR203312). MC is supported by a BHF Career Development
297 Fellowship and the NIHR. JMT is supported by a Wellcome Trust Clinical Research Career
298 Development Fellowship (211100/Z/18/Z) and the Cambridge BHF Centre for Research
299 Excellence (18/1/34212). JHFR is part-supported by the NIHR Cambridge Biomedical
300 Research Centre, the British Heart Foundation, HEFCE, the EPSRC and the Wellcome Trust.
301 NRE is supported by a Stroke Association Senior Clinical Lectureship [SA-SCL-MED-
302 22\100006].

303

304 **Disclosures**

305

306 None

1. Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, Tokgözoğlu L, Lewis EF. Atherosclerosis. *Nature Reviews Disease Primers*. 2019;5:56. doi: 10.1038/s41572-019-0106-z
2. Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandebroek K, Benito-Vicente A, Martín C. Pathophysiology of Atherosclerosis. *Int J Mol Sci*. 2022;23. doi: 10.3390/ijms23063346
3. Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, Gale CP, Maggioni AP, Petersen SE, Huculeci R, et al. European Society of Cardiology: cardiovascular disease statistics 2021. *European Heart Journal*. 2022;43:716-799. doi: 10.1093/eurheartj/ehab892
4. Eisen A, Bhatt DL, Steg PG, Eagle KA, Goto S, Guo J, Smith SC, Ohman EM, Scirica BM. Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. *J Am Heart Assoc*. 2016;5. doi: 10.1161/jaha.116.004080
5. Kannel WB, Feinleib M. Natural history of angina pectoris in the Framingham study. Prognosis and survival. *Am J Cardiol*. 1972;29:154-163. doi: 10.1016/0002-9149(72)90624-8
6. Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. *Neurology*. 2005;64:817-820. doi: 10.1212/01.Wnl.0000152985.32732.Ee
7. Johansson E, Cuadrado-Godia E, Hayden D, Bjellerup J, Ois A, Roquer J, Wester P, Kelly PJ. Recurrent stroke in symptomatic carotid stenosis awaiting revascularization: A pooled analysis. *Neurology*. 2016;86:498-504. doi: 10.1212/wnl.0000000000002354
8. Insull W. The Pathology of Atherosclerosis: Plaque Development and Plaque Responses to Medical Treatment. *The American Journal of Medicine*. 2009;122:S3-S14. doi: <https://doi.org/10.1016/j.amjmed.2008.10.013>
9. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of Vulnerable/Unstable Plaque. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2010;30:1282-1292. doi: 10.1161/ATVBAHA.108.179739
10. Fleg JL, Stone GW, Fayad ZA, Granada JF, Hatsukami TS, Kolodgie FD, Ohayon J, Pettigrew R, Sabatine MS, Tearney GJ, et al. Detection of high-risk atherosclerotic

- plaque: report of the NHLBI Working Group on current status and future directions. *JACC Cardiovasc Imaging*. 2012;5:941-955. doi: 10.1016/j.jcmg.2012.07.007
11. Deng F, Mu C, Yang L, Li H, Xiang X, Li K, Yang Q. Carotid plaque magnetic resonance imaging and recurrent stroke risk: A systematic review and meta-analysis. *Medicine (Baltimore)*. 2020;99:e19377. doi: 10.1097/md.00000000000019377
 12. Redgrave JN, Gallagher P, Lovett JK, Rothwell PM. Critical cap thickness and rupture in symptomatic carotid plaques: the oxford plaque study. *Stroke*. 2008;39:1722-1729. doi: 10.1161/strokeaha.107.507988
 13. Vancheri F, Longo G, Vancheri S, Danial JSH, Henein MY. Coronary Artery Microcalcification: Imaging and Clinical Implications. *Diagnostics (Basel)*. 2019;9. doi: 10.3390/diagnostics9040125
 14. Fox KAA, Metra M, Morais J, Atar D. The myth of 'stable' coronary artery disease. *Nature Reviews Cardiology*. 2020;17:9-21. doi: 10.1038/s41569-019-0233-y
 15. Akers EJ, Nicholls SJ, Di Bartolo BA. Plaque Calcification. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2019;39:1902-1910. doi: 10.1161/ATVBAHA.119.311574
 16. Shi X, Gao J, Lv Q, Cai H, Wang F, Ye R, Liu X. Calcification in Atherosclerotic Plaque Vulnerability: Friend or Foe? *Frontiers in Physiology*. 2020;11. doi: 10.3389/fphys.2020.00056
 17. Kawtharany L, Bessueille L, Issa H, Hamade E, Zibara K, Magne D. Inflammation and Microcalcification: A Never-Ending Vicious Cycle in Atherosclerosis? *Journal of Vascular Research*. 2022;59:137-150. doi: 10.1159/000521161
 18. Hansson GK, Libby P, Tabas I. Inflammation and plaque vulnerability. *J Intern Med*. 2015;278:483-493. doi: 10.1111/joim.12406
 19. Tzolos E, Dweck MR. ¹⁸F-Sodium Fluoride (¹⁸F-NaF) for Imaging Microcalcification Activity in the Cardiovascular System. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2020;40:1620-1626. doi: doi:10.1161/ATVBAHA.120.313785
 20. Sriranjana RS, Tarkin JM, Evans NR, Le EPV, Chowdhury MM, Rudd JHF. Atherosclerosis imaging using PET: Insights and applications. *British Journal of Pharmacology*. 2021;178:2186-2203. doi: <https://doi.org/10.1111/bph.14868>

21. Høilund-Carlsen PF, Sturek M, Alavi A, Gerke O. Atherosclerosis imaging with (18)F-sodium fluoride PET: state-of-the-art review. *Eur J Nucl Med Mol Imaging*. 2020;47:1538-1551. doi: [10.1007/s00259-019-04603-1](https://doi.org/10.1007/s00259-019-04603-1)
22. Blau M, Ganatra R, Bender MA. 18F-fluoride for bone imaging. *Seminars in Nuclear Medicine*. 1972;2:31-37. doi: [https://doi.org/10.1016/S0001-2998\(72\)80005-9](https://doi.org/10.1016/S0001-2998(72)80005-9)
23. Schmid K, McSharry WO, Pameijer CH, Binette JP. Chemical and physicochemical studies on the mineral deposits of the human atherosclerotic aorta. *Atherosclerosis*. 1980;37:199-210. doi: [https://doi.org/10.1016/0021-9150\(80\)90005-2](https://doi.org/10.1016/0021-9150(80)90005-2)
24. Bischetti S, Scimeca M, Bonanno E, Federici M, Anemona L, Menghini R, Casella S, Cardellini M, Ippoliti A, Mauriello A. Carotid plaque instability is not related to quantity but to elemental composition of calcification. *Nutr Metab Cardiovasc Dis*. 2017;27:768-774. doi: [10.1016/j.numecd.2017.05.006](https://doi.org/10.1016/j.numecd.2017.05.006)
25. Irkle A, Vesey AT, Lewis DY, Skepper JN, Bird JL, Dweck MR, Joshi FR, Gallagher FA, Warburton EA, Bennett MR, et al. Identifying active vascular microcalcification by (18)F-sodium fluoride positron emission tomography. *Nat Commun*. 2015;6:7495. doi: [10.1038/ncomms8495](https://doi.org/10.1038/ncomms8495)
26. Derlin T, Richter U, Bannas P, Begemann P, Buchert R, Mester J, Klutmann S. Feasibility of 18F-sodium fluoride PET/CT for imaging of atherosclerotic plaque. *J Nucl Med*. 2010;51:862-865. doi: [10.2967/jnumed.110.076471](https://doi.org/10.2967/jnumed.110.076471)
27. Morbelli S, Fiz F, Piccardo A, Picori L, Massollo M, Pestarino E, Marini C, Cabria M, Democrito A, Cittadini G, et al. Divergent determinants of 18F-NaF uptake and visible calcium deposition in large arteries: relationship with Framingham risk score. *The International Journal of Cardiovascular Imaging*. 2014;30:439-447. doi: [10.1007/s10554-013-0342-3](https://doi.org/10.1007/s10554-013-0342-3)
28. Fiz F, Morbelli S, Piccardo A, Bauckneht M, Ferrarazzo G, Pestarino E, Cabria M, Democrito A, Riondato M, Villavecchia G, et al. ¹⁸F-NaF Uptake by Atherosclerotic Plaque on PET/CT Imaging: Inverse Correlation Between Calcification Density and Mineral Metabolic Activity. *J Nucl Med*. 2015;56:1019-1023. doi: [10.2967/jnumed.115.154229](https://doi.org/10.2967/jnumed.115.154229)
29. Mayer M, Borja AJ, Hancin EC, Auslander T, Revheim ME, Moghbel MC, Werner TJ, Alavi A, Rajapakse CS. Imaging Atherosclerosis by PET, With Emphasis on the Role of

- FDG and NaF as Potential Biomarkers for This Disorder. *Front Physiol.* 2020;11:511391. doi: 10.3389/fphys.2020.511391
30. Bhakta S WE, Evans NR. 18F-Sodium Fluoride Uptake on PET/CT in Symptomatic versus Asymptomatic Atherosclerotic Disease: a Meta-Analysis. PROSPERO: International prospective register of systematic reviews. www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=42023451363. 2023.
31. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ.* 2021;372:n71. doi: 10.1136/bmj.n71
32. Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023). In: Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, ed. Available from www.training.cochrane.org/handbook.: Cochrane; 2023.
33. ROBINS-E Development Group (Higgins J MR, Rooney A, Taylor K, Thayer K, Silva R, Lemeris C, Akl A, Arroyave W, Bateson T, Berkman N, Demers P, Forastiere F, Glenn B, Hróbjartsson A, Kirrane E, LaKind J, Luben T, Lunn R, McAleenan A, McGuinness L, Meerpohl J, Mehta S, Nachman R, Obbagy J, O'Connor A, Radke E, Savović J, Schubauer-Berigan M, Schwingl P, Schunemann H, Shea B, Steenland K, Stewart T, Straif K, Tilling K, Verbeek V, Vermeulen R, Viswanathan M, Zahm S, Sterne J). Risk Of Bias In Non-randomized Studies - of Exposure (ROBINS-E). Launch version, 20 June 2023. Available from: <https://www.riskofbias.info/welcome/robins-e-tool>.
34. McGrath S, Katzenschlager S, Zimmer AJ, Seitel A, Steele R, Benedetti A. Standard error estimation in meta-analysis of studies reporting medians. *Stat Methods Med Res.* 2023;32:373-388. doi: 10.1177/09622802221139233
35. Viechtbauer W. Conducting meta-analyses in R with the metafor package. *Journal of Statistical Software.* 2010;36:1-48. doi: <https://doi.org/10.18637/jss.v036.i03>
36. McGrath S ZX, Katzenschlager S, Ozturk O, Steele R, Benedetti A. *metamedian: Meta-Analysis of Medians; R package version 1.1.0.* 2023.
37. Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. *Campbell Syst Rev.* 2022;18:e1230. doi: 10.1002/cl2.1230

38. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. *Syst Rev*. 2016;5:210. doi: 10.1186/s13643-016-0384-4
39. Kaczynski J, Sellers S, Seidman MA, Syed M, Dennis M, McNaught G, Jansen M, Semple SI, Alcaide-Corral C, Tavares AAS, et al. (18)F-NaF PET/MRI for Detection of Carotid Atheroma in Acute Neurovascular Syndrome. *Radiology*. 2022;305:137-148. doi: 10.1148/radiol.212283
40. Moss A, Daghem M, Tzolos E, Meah MN, Wang K-L, Bularga A, Adamson PD, Kwiecinski J, Fletcher A, Dawson D, et al. Coronary Atherosclerotic Plaque Activity and Future Coronary Events. *JAMA Cardiology*. 2023;8:755-764. doi: 10.1001/jamacardio.2023.1729
41. Bucorius J, Hyafil F, Verberne HJ, Slart RHJA, Lindner O, Sciagra R, Agostini D, Übleis C, Gimelli A, Hacker M, on behalf of the Cardiovascular Committee of the European Association of Nuclear M. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis. *European Journal of Nuclear Medicine and Molecular Imaging*. 2016;43:780-792. doi: 10.1007/s00259-015-3259-3
42. Saba L, Loewe C, Weikert T, Williams MC, Galea N, Budde RPJ, Vliegenthart R, Velthuis BK, Francone M, Bremerich J, et al. State-of-the-art CT and MR imaging and assessment of atherosclerotic carotid artery disease: standardization of scanning protocols and measurements-a consensus document by the European Society of Cardiovascular Radiology (ESCR). *Eur Radiol*. 2023;33:1063-1087. doi: 10.1007/s00330-022-09024-7
43. Kaul P, Douglas PS. Atherosclerosis Imaging. *Circulation: Cardiovascular Imaging*. 2009;2:150-160. doi: doi:10.1161/CIRCIMAGING.109.850263
44. Evans NR, Tarkin JM, Le EP, Sriranjana RS, Corovic A, Warburton EA, Rudd JH. Integrated cardiovascular assessment of atherosclerosis using PET/MRI. *The British Journal of Radiology*. 2020;93:20190921. doi: 10.1259/bjr.20190921
45. McKenney-Drake ML, Moghbel MC, Paydary K, Alloosh M, Houshmand S, Moe S, Salavati A, Sturek JM, Territo PR, Weaver C, et al. (18)F-NaF and (18)F-FDG as molecular probes in the evaluation of atherosclerosis. *Eur J Nucl Med Mol Imaging*. 2018;45:2190-2200. doi: 10.1007/s00259-018-4078-0

46. Bing R. SALTIRE II: Bisphosphonates and RANKL Inhibition in Aortic Stenosis. ClinicalTrials.gov. <https://clinicaltrials.gov/study/NCT02132026>. 2014.
47. Montanaro M, Scimeca M, Anemona L, Servadei F, Giacobbi E, Bonfiglio R, Bonanno E, Urbano N, Ippoliti A, Santeusano G, et al. The Paradox Effect of Calcification in Carotid Atherosclerosis: Microcalcification is Correlated with Plaque Instability. *Int J Mol Sci*. 2021;22. doi: 10.3390/ijms22010395
48. Dweck MR, Joshi NV, Jenkins W, Jones C, Chow MWL, Fletcher A, van Beek EJ, Boon NA, Rudd JHF, Newby DE. Assessment of calcification and inflammation with positron emission tomography in aortic stenosis and atherosclerosis. *The Lancet*. 2013;381:S11. doi: 10.1016/S0140-6736(13)60451-1
49. Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, Yeoh SE, Wallace W, Salter D, Fletcher AM, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. *Lancet*. 2014;383:705-713. doi: 10.1016/S0140-6736(13)61754-7
50. Quirce R, Martinez-Rodriguez I, Banzo I, Jimenez-Bonilla J, Martinez-Amador N, Ibanez-Bravo S, Lopez-Defillo J, Jimenez-Alonso M, Revilla MA, Carril JM. New insight of functional molecular imaging into the atheroma biology: 18F-NaF and 18F-FDG in symptomatic and asymptomatic carotid plaques after recent CVA. Preliminary results. *Clin Physiol Funct Imaging*. 2016;36:499-503. doi: 10.1111/cpf.12254
51. Vesey AT, Jenkins WS, Irkle A, Moss A, Sng G, Forsythe RO, Clark T, Roberts G, Fletcher A, Lucatelli C, et al. (18)F-Fluoride and (18)F-Fluorodeoxyglucose Positron Emission Tomography After Transient Ischemic Attack or Minor Ischemic Stroke: Case-Control Study. *Circ Cardiovasc Imaging*. 2017;10:e004976. doi: 10.1161/CIRCIMAGING.116.004976
52. Andrews J, Moss A, Doris M, Pawade T, Adamson P, MacNaught G, Lucatelli C, Newby D, Dweck M. 18 18F-fluoride pet MR in valvular and coronary heart disease; a pilot investigational study. *Heart*. 2018;104:A12-A12. doi: 10.1136/heartjnl-2018-BCVI.33
53. Marchesseau S, Seneviratna A, Sjöholm AT, Qin DL, Ho JXM, Hausenloy DJ, Townsend DW, Richards AM, Totman JJ, Chan MYY. Hybrid PET/CT and PET/MRI imaging of vulnerable coronary plaque and myocardial scar tissue in acute myocardial infarction. *J Nucl Cardiol*. 2018;25:2001-2011. doi: 10.1007/s12350-017-0918-8

54. Sood A, JOIS A, Singhal M, Mittal B, Manoj R, Rana N, RAWAT D, Kasinadhuni G, Krisnappa D. Role of ¹⁸F-NaF PET/CT based imaging of atherosclerotic plaques in patients with myocardial infarction and chronic stable angina. *Journal of Nuclear Medicine*. 2018;59:1509-1509.
55. Chowdhury MM, Tarkin JM, Albaghdadi MS, Evans NR, Le EPV, Berrett TB, Sadat U, Joshi FR, Warburton EA, Buscombe JR, et al. Vascular Positron Emission Tomography and Restenosis in Symptomatic Peripheral Arterial Disease: A Prospective Clinical Study. *JACC Cardiovasc Imaging*. 2020;13:1008-1017. doi: 10.1016/j.jcmg.2019.03.031
56. Evans NR, Tarkin JM, Chowdhury MM, Le EPV, Coughlin PA, Rudd JHF, Warburton EA. Dual-Tracer Positron-Emission Tomography for Identification of Culprit Carotid Plaques and Pathophysiology In Vivo. *Circ Cardiovasc Imaging*. 2020;13:e009539. doi: 10.1161/CIRCIMAGING.119.009539
57. Cocker MS, Spence JD, Hammond R, Wells G, deKemp RA, Lum C, Adeeko A, Yaffe MJ, Leung E, Hill A, et al. [(18)F]-NaF PET/CT Identifies Active Calcification in Carotid Plaque. *JACC Cardiovasc Imaging*. 2017;10:486-488. doi: 10.1016/j.jcmg.2016.03.005
58. Hop H, de Boer SA, Reijrink M, Kamphuisen PW, de Borst MH, Pol RA, Zeebregts CJ, Hillebrands JL, Slart R, Boersma HH, et al. (18)F-sodium fluoride positron emission tomography assessed microcalcifications in culprit and non-culprit human carotid plaques. *J Nucl Cardiol*. 2019;26:1064-1075. doi: 10.1007/s12350-018-1325-5
59. Kim JM, Lee ES, Park KY, Seok JW, Kwon OS. Analysis of (18)F-Fluorodeoxyglucose and (18)F-Fluoride Positron Emission Tomography in Korean Stroke Patients with Carotid Atherosclerosis. *J Lipid Atheroscler*. 2019;8:232-241. doi: 10.12997/jla.2019.8.2.232
60. Mechtouff L, Sigovan M, Douek P, Costes N, Le Bars D, Mansuy A, Haesebaert J, Bani-Sadr A, Tordo J, Feugier P, et al. Simultaneous assessment of microcalcifications and morphological criteria of vulnerability in carotid artery plaque using hybrid (18)F-NaF PET/MRI. *J Nucl Cardiol*. 2022;29:1064-1074. doi: 10.1007/s12350-020-02400-0

Table 1 Included study characteristics for studies comparing symptomatic to asymptomatic disease between arteries in the same participant

Author and Year	Article Type	Arterial Territory and Type of Symptomatic Disease	How was the symptomatic disease diagnosed?	Enrolled population demographics - number of participants, mean age and sex	Types of imaging used	Symptomatic patients completing 18F-NaF PET imaging (n), number of symptomatic plaques	Time from onset of symptoms to scan	Comparator population, number of comparator data points (n)	Dose of NaF injected, Uptake time	Imaging protocol	Endpoint measure	Blood Pool Measurement	Findings
-----------------	--------------	--	--	---	-----------------------	--	-------------------------------------	---	-----------------------------------	------------------	------------------	------------------------	----------

Dweck ⁴⁸ , 2013	Abstract	Coronary, myocardial infarction	Not listed	n = 15, age/sex data not listed	FDG and NaF PET-CT	15, 15	Not listed	Maximum uptake elsewhere in the coronary arteries, 15	Not listed	Not listed	TBR (no further description)	Not listed	Increased uptake noted at the culprit lesion compared with the maximum uptake elsewhere in the coronary arteries (TBR median 1.56)
-------------------------------	----------	---------------------------------	------------	---------------------------------	--------------------	--------	------------	---	------------	------------	------------------------------	------------	--

													[IQR 1.49- 1.82] vs 1.23 [1.15- 1.48], p=0.02)
Joshi ⁴⁹ , 2014	Pape r	Corona ry, ST- elevatio n myocar dial infarcti on or non-ST- elevatio n myocar dial	Clinical guideli ne criteria	n = 40, age 62 ± 8 years, 93% male	FDG and NaF PET- CT, CT coron ary angiog ram, coron ary angiog ram	40, 40	Media n 8 [3- 10] days	Maxim um signal value of the non- culprit vessels, 40	123 ± 5 MBq , 60 ± 9 minu tes	Electrocard iograph- gated PET images were reconstruct ed in diastole	TBRmax - ROIs drawn around all major (diamet er >2 mm) epicardi al vessels on 3	correcte d for blood pool activity in the superior vena cava	18F-NaF activity in the culprit plaque was 34% higher than the maximu m activity recorde d

		infarction								mm axial slices just beyond the discernible adventitial border; ¹⁸ F-NaF uptake in the culprit plaque was compared with the	anywhere else in the coronary vasculature (maximum TBR 1.66 [1.40-2.25] vs 1.24 [1.06-1.38], p<0.0001)
--	--	------------	--	--	--	--	--	--	--	--	--

											highest value in any of the non-culprit vessels		
Quirce ⁵⁰ , 2016	Short Report	Carotid, stroke or transient ischemic attack	Not listed	n = 9, age range 50-83 years, 88.9% male	FDG + NaF PET-CT	9, 9	Within 10 days	Contralateral artery, 9	370 MBq, 180 minutes	beds including the head and cervical region were acquired at 5 min per bed. Image data were reconstructed, and	TBRmax using SUVmax in the plaque	SUVmax in the lumen of the superior vena cava	Mean TBR was 2.12 ± 0.44 in the symptomatic plaques and 1.85 ± 0.46 in the asymptomatic

										attenuation correction was done after applying iterative reconstruction methods with 2 iterations and 16 subsets.			matic (P = 0.22)
Vesey ⁵¹ , 2017	Paper	Carotid, stroke or transient	Not listed	n = 26, demographic data listed separately	FDG + NaF PET-CT, CT angiogram	14, 14	Not listed	Contralateral artery, 14	244.5 ± 12.66 MBq	PET acquisition covering 2 bed positions, 15 minutes	Three ROIs drawn on adjacent 3-mm	average of 5 ROIs within the lumen of the	Culprit 2.75 [2.39-3.21] vs contralateral

		ischemic attack	<p>ely: symptomatic carotid disease: n = 18, age 71.7 ± 12.3 years, 66.7% male; asymptomatic carotid disease: n = 8, age 66.1 ± 12.5 years,</p>				<p>64.6 ± 5.6 minutes</p>	<p>per bed. PET data reconstructed with ordered subset expectation maximization+point spread function modeling+time-of-flight; 2 iterations and 21 subsets; matrix size 200x200; 5</p>	<p>axial slices. If plaque present, ROIs centered on area of highest uptake. If no plaque present, uptake in the proximal 1 cm of internal carotid</p>	<p>superior vena cava</p>	<p>2.42 [2.02-2.82]; p=0.014 for log10 transformation of original data</p>
--	--	-----------------	---	--	--	--	---------------------------	--	--	---------------------------	--

				50% male						mm full-width half-maximum Gaussian smoothing.	artery, just distal to the bifurcation was quantified.		
Andrews ⁵² , 2018	Abstract	Coronary, myocardial infarction	Clinical + imaging	n = 13, age/sex data not listed	NaF PET-MRI, MR angiogram	13, 13	Not listed	Vessel proximal to culprit plaque, 13	Not listed	PET data acquired in list mode, Dixon attenuation correction technique	TBRmax - focal 18F-NaF uptake in culprit vessel	Not listed	13/13 patients with MI had focal 18F-NaF uptake in the culprit vessel with a TBR max

													greater than the proximal referent vessel (TBRmax 1.64±0.47 vs 1.16±0.26, p=0.004)
Marcheseau ⁵³ , 2018	Paper	Coronary, ST-elevation myocardial infarction	Clinical guideline criteria	n = 10, age 48 ± 7 years, 90% male	NaF PET-MRI + PET-CT, cardiac MRI, CT	8, 8	Median 13.5 (range 9-24) days	Non-culprits, 25	2.95 ± 0.21 mCi, 108 ± 21 minutes	10 minute acquisition, one bed position centered over the heart; reconstruct	TBRmax - ratio of the calcium region maximum SUV over the	Mean SUV of the corresponding vessel minus the	TBR of the culprit lesions was significantly higher

					coronary artery calcium score scan				ed using an iterative reconstruction (3 iterations, 21 subsets, 2 mm pixel size, 2 mm FWHM Gaussian filter), with attenuation and scatter corrections included as well as Time of Flight and Point	corresponding vessel (excluding the calcium ROIs) mean SUV	previously selected ROI	than the TBR for non-culprit lesions with an average value of 2.11 for culprit (± 0.42) and 1.36 (± 0.30) for non-culprit (P value < 0.001)
--	--	--	--	--	------------------------------------	--	--	--	--	--	-------------------------	--

										Spread Function correction			
Sood ⁵⁴ , 2018	Abstract	Coronary, myocardial infarction	Clinical guideline criteria	n = 24, age/sex data not listed	NaF PET- CT, CT coronary angiogram	24, 24	Not listed	Non- culprit vessels, 24	3-5 mCi, 45 minutes	acquired in list mode	TBRmax from SUVmax of vessels	Not listed	The difference in median TBR of culprit vessels (1.46, IQR: 1.29- 1.73) and non- culprit vessels (0.99, IQR:

													0.80-1.02) was statistically significant (p-value <0.0001)
Chowdhury ⁵⁵ , 2020	Paper	Superficial femoral artery, peripheral vascular disease (intermittent	Clinical + imaging	n = 50, median age 70 [65-78] years, 66% male	FDG and NaF PET-CT, CT angiogram	40, 40	Not applicable - participants included with intermittent	Contralateral artery, 40	Mean 401.4 MBq, 60 minutes	PET data acquired from iliac crest to tibial plateau, 4 minute acquisition per bed position	TBRmax - ROIs placed on adjacent axial images, SUVmax per slice recorded	5 ROIs drawn in the center of the common femoral vein	Median baseline 18F-NaF TBRmax was 1.78 (IQR: 1.62 to 2.50); 1.54 (IQR: 1.36 to

		claudication or critical limb ischemia)					claudication						1.72) in the contralateral (untreated, asymptomatic) limb, no p value reported
Evans ⁵⁶ , 2020	Paper	Carotid, stroke	Clinical + imaging	n = 31, age 74.8 ± 9.7 years, 69.2% male	FDG and NaF PET-CT, CT angiogram	26, 26	8.5 ± 4.2 days to initial scan, 53.8% had NaF	Contralateral artery, 26	125 MBq, 60 minutes	ROIs drawn along the common carotid and internal carotid artery to encompass	MDS TBRmax : MDS uses most diseased 9 mm, based	mid-luminal ROIs in the jugular vein over 5 contiguous	NaF uptake was higher in culprit plaques than nonculp

							PET first, median 1 [IQR 1.75] days between NaF and FDG scans		the region 0.9 cm proximal and 3 cm distal to the carotid bifurcation	on tracer uptake 3 contiguous axial slices where the central ROI has the highest uptake within the artery	us 3 mm slices	rit plaques when considering MDS TBRmax - mean 2.85 +/- 1.15 vs 2.34 +/- 0.64, p<0.01
--	--	--	--	--	--	--	---	--	---	---	----------------	---

Kaczynski ³⁹ , 2022	Paper	Carotid, stroke, transient ischemic attack or amaurosis fugax	Clinical + imaging	n = 110, age 68 ± 10 years, 64% male	NaF PET-MRI, MR angiogram	110, 110	Not listed	Contralateral artery, 110	125 MBq, 60 minutes	PET data obtained using list-mode acquisition with two 15-min beds positions covering the carotid arteries (aortic arch to skull base). Images reconstructed with corrections applied for	TBRmax - uptake measured in a spherical VOI centered on the most severe stenosis	averaged from 3 ROIs within the brachiocephalic or internal jugular veins	Culprit vessels had a higher 18F-NaF uptake than non-culprit vessels (TBRmax 1.38 [1.12, 1.82] versus 1.26 [0.99, 1.66], p=.04)
--------------------------------	-------	---	--------------------	--------------------------------------	---------------------------	----------	------------	---------------------------	---------------------	---	--	---	---

									attenuatio n, dead time, scatter and random coincidenc es (matrix size 256x256, ordered subset expectatio n maximizati on reconstruct ion with point spread function		
--	--	--	--	--	--	--	--	--	---	--	--

										modelling, 3 iterations, 21 subsets, 2mm Gaussian filtration)			
--	--	--	--	--	--	--	--	--	--	---	--	--	--

Table 2 Included study characteristics for studies comparing symptomatic to asymptomatic disease within and between participants

Author , Year	Article Type	Arterial Territory, Type of Symptomatic Disease	How symptomatic disease was diagnosed	Participant demographics - number of participants, mean age and sex	Types of imaging used	Symptomatic patients complete 18F- NaF PET imaging (n), number of symptomatic plaques	Time from onset of symptoms to scan	Comparator population, number of comparator data points (n)	Dose of NaF injected, Uptake time	PET Imaging protocol	Endpoint measure	Blood Pool Measurement	Findings
------------------	-----------------	--	---	--	--------------------------------	--	---	--	---	----------------------------	---------------------	------------------------------	----------

Irkle ²⁵ , 2015	Paper	Carotid, stroke or transient ischemic attack	Not listed	n = 7, age 68.9 ± 13.5 years, 57.1% male	NaF PET- CT	5, 5	16.4 ± 8.0 days	PET- positive regions in asymptomatic participants, 2	Not listed	PET scanning performed for 75 minutes following tracer injection	"Mean of Max" TBR	Not listed	Individual participant data reported, and converted to median/interquartile range: symptomatic disease 2.48 [1.80- 3.33] vs asymptomatic disease 2.41 [2.32- 2.49], no p value.
-------------------------------	-------	---	---------------	---	-------------------	------	-----------------------	---	---------------	---	----------------------------	---------------	--

Cocker ⁵ 7, 2017	Short Report	Carotid, stroke or transient ischemic attack	Not listed	n = 11, age 69 ± 5 years, 72.7% male	NaF PET-CT, CT angiogram	9, 9	Not listed	Contralateral artery or asymptomatic carotid arteries, 11	3 MBq/kg, 60 minutes	PET/CT imaging was performed, followed by CT angiography	TBRmax - maximum 18F-NaF activity for each plaque	Normalized to mean SUV in internal jugular vein	Plaque associated with symptoms had evidence for greater 18F-NaF uptake than plaque not associated with symptoms (TBRmax: 3.75 ± 1.10 vs. 2.79 ± 0.60; p = 0.04)
--------------------------------	--------------	--	------------	--------------------------------------	--------------------------	------	------------	---	----------------------	--	---	---	--

Hop ⁵⁸ , 2019	Paper	Carotid, stroke	Clinical + imaging	n = 23, median age 72 [61-75] years, 85% male	NaF micro PET, micro CT	17, 17	21 ± 14 days	Endarter ectomy specimen s from non- culprit plaques, 6	49.4 ± 7.2 MBq (incub ated), 60 minute s	MicroPE T emissio n scan for 30 minutes , reconstr ucted using OSEM2 D (4 iteratio ns and 16 subsets) , after being normali zed and	%Inc/g – Perce ntage uptak e of total incuba tion dose per gram of tissue (%Inc/ g).	N/A	Average 18F-NaF uptake was similar in culprit and non-culprit carotid plaques (median 2.32 %Inc/g [IQR 1.98 to 2.81] vs. median 2.35 %Inc/g [IQR 1.77 to 3.00], p = 0.916)
-----------------------------	-------	--------------------	--------------------------	---	-------------------------------------	--------	--------------------	--	---	--	---	-----	--

										corrected for attenuation and decay of radioactivity.			
Kim ⁵⁹ , 2019	Paper	Carotid, stroke or transient ischemic attack	Clinical + imaging	n = 18, demographic data listed separately: symptomatic group: n = 10, age 72.9	FDG and NaF PET-CT, CT angiogram	10, 10	Median 17 (range 3-37) days	Contralateral artery or asymptomatic carotid arteries in those with an alternative cause	259-370 MBq, 60 minutes	PET images acquired at 5 min/bed for the head and 1 min/bed from the skull	NaF TBRmax at the largest atheroma segment	SUV of aortic blood	NaF TBRmax at the largest atheroma segment in symptomatic vs asymptomatic plaques: 1.53 ± 0.54 vs 1.39 ±

				± 8.2 years, 50% male; asymptomatic group: n = 8, age 77.1 ± 10.9 years, 50% male				of stroke, 26		base to the proximal thigh			0.45, p = 0.37
Mechto uff ⁶⁰ , 2022	Pap er	Carotid, stroke or transie nt ischemi c attack	Not listed	n = 12, age 68 ± 10 years, 75% male	NaF PET- MRI, MR angio gram	6, 6	9.2 ± 6.2 days	Contralat eral artery and carotid arteries of	3 MBq/k g, 60 minute s	15 minute PET acquisiti on	TBRm ax measu red using 3 ROIs center	mean of five ROIs in the mid lumen of the superior	18F-NaF uptake was higher in culprit plaques compared to

								asymptomatic control participants, 18			ed on the area of highest uptake in the plaque	vena cava	nonculprit plaques (median TBR 2.6 [2.2-2.8] vs 1.7 [1.3-2.2]; P = 0.03)
--	--	--	--	--	--	--	--	---------------------------------------	--	--	--	-----------	--

Embase <1996 to 2023 Week 30>

Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations, Daily and Versions <1946 to August 02, 2023>

- 1 (18F* or NaF or \$F-NaF*).ti,ab.
- 2 (PET or positron*).ti,ab.
- 3 (athero* or acute or microcalcif* or plaque).ti,ab.
- 4 (culprit or symptom* or active).ti,ab.
- 5 1 and 2 and 3 and 4
- 6 (editorial* or case report* or review* or meta-analysis).pt.
- 7 5 not 6

Figure 1 Search strategy performed for systematic review and meta-analysis




Figure 2 Funnel plot of studies included in Table 1




Figure 3 Funnel plot of studies included in Table 2




Figure 4 PRISMA diagram of systematic review search synthesis




Figure 5 Forest Plot of included studies summarising data comparing symptomatic and asymptomatic atherosclerotic disease within individuals. SMD = standardized mean difference, CI = confidence intervals





Figure 6 Forest Plot of included studies summarizing data comparing symptomatic and asymptomatic atherosclerotic disease within individuals.

SMD = standardized mean difference, CI = confidence intervals



Supplementary Figure 1 - Summary plot of Risk of Bias assessment using ROBINS-E (Risk Of Bias In Non-randomized Studies - of Exposures) tool